CD8A and melanoma: Examination of tumor infiltrates after tremelimumab therapy revealed an increase in activated CD8+ T cells in many melanoma patients; while not Tregs, this non-specific increase was observed in a greater proportion of patients than patients deriving any clinical benefit and showed no correlation with either tumor progression or regression (36).